China’s NMPA Proposes Rewards for Internal Whistleblowers in Drug and Medical Device Safety Reporting

The National Medical Products Administration (NMPA) of China has issued a draft proposal for the “Notice on Rewarding Internal Whistleblowers for Reporting on the Quality and Safety Issues of Drugs and Medical Devices.” The bureau is seeking public feedback from October 10 to November 9, 2024. This initiative encourages entities involved in the research, production, and operation of drugs and medical devices, as well as users and third-party platform providers for online transactions, to report significant violations of quality and safety standards to regulatory authorities. Organizations are advised to prominently display reporting channels at their R&D, production, and operational locations. Localities are also encouraged to establish special channels for handling reports from internal whistleblowers. Reports deemed to lead to major illegal behavior will be prioritized for verification and handling. For confirmed cases, the drug regulatory department will reward eligible internal whistleblowers, with a maximum reward of RMB 1 million (USD 141,298) per case. – Flcube.com